Showing posts with label phase11. Show all posts
Showing posts with label phase11. Show all posts
Friday, January 22, 2010
Trial design for evaluation of novel targeted therapies
"Conclusions:Alternatives to traditional phase II trial design including alternative end points, randomized designs, biomarkers, and imaging tools should allow ineffective agents to be discarded and promising agents to undergo further investigation."
Subscribe to:
Posts
(
Atom
)
